Alnylam Pharmaceuticals Inc (ALNY)vsEli Lilly and Company (LLY)
ALNY
Alnylam Pharmaceuticals Inc
$267.47
-5.54%
HEALTHCARE · Cap: $41.79B
LLY
Eli Lilly and Company
$1,146.37
-2.78%
HEALTHCARE · Cap: $1.08T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1585% more annual revenue ($72.25B vs $4.29B). LLY leads profitability with a 35.0% profit margin vs 12.6%. ALNY appears more attractively valued with a PEG of 0.54. LLY earns a higher WallStSmart Score of 76/100 (B+).
ALNY
Strong Buy65
out of 100
Grade: B-
LLY
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.3%
Fair Value
$2346.12
Current Price
$267.47
$2078.65 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Growing faster than its price suggests
Strong operational efficiency at 23.0%
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 33.2x book value
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 32.8x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth, PEG Ratio. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 78.8x leaves little room for execution misses.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 43.9x leaves little room for execution misses.
Key Dynamics to Monitor
LLY carries more volatility with a beta of 0.51 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (76/100 vs 65/100), backed by strong 35.0% margins and 55.5% revenue growth. ALNY offers better value entry with a 86.3% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?